Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch

Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch A real-world study showed patients with inflammatory bowel disease (IBD) or chronic inflammatory rheumatic disease treated with reference adalimumab who were switched to the biosimilar CT-P17 generally believed the switch was a treatment necessity. Higher satisfaction rates were observed among those who were […]

News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months

News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence, as well as equivalent efficacy, safety, and immunogenicity compared with the reference product among a cohort of postmenopausal women with osteoporosis for up to 18 months of treatment, according to […]

Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment

Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment In an interview with HCPLive, Jacques-Eric Gottenberg, MD, PhD, associated with the Department of Rheumatology at Strasbourg University Hospital, France, discusses the results of a study presented at the 2024 European Congress of Rheumatology (EULAR) evaluating the efficacy and […]

Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout

Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout Among a cohort of Chinese patients with gout, dotinurad 4 mg demonstrated superiority to febuxostat 40 mg in lowering serum uric acid (sUA), according to data presented at the 2024 European Congress of Rheumatology (EULAR). Additionally, dotinurad 2 mg was non-inferior to febuxostat and […]

Newly reported from EULAR 2024: SEL-212 Demonstrates Clinical Safety, Efficacy in Gout

Newly reported from EULAR 2024: SEL-212 Demonstrates Clinical Safety, Efficacy in Gout Both SEL-110 high dose (HD, 0.15 mg/kg) or low dose (LD, 0.1 mg/kg) with concomitant SEL-037 (0.2 mg/kg), known as SEL-212, demonstrated clinical efficacy and safety among a cohort of patients with gout refractory to standard treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). As […]

From EULAR 2024 – Gerd Burmester, MD: Long-Term Data Supports Upadacitinib’s Safety in Rheumatic Disease Treatment

From EULAR 2024 – Gerd Burmester, MD: Long-Term Data Supports Upadacitinib’s Safety in Rheumatic Disease Treatment In an interview with HCPLive, Gerd Burmester, MD, professor of medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University of Berlin, and Humboldt University of Berlin, Germany, discusses the results of a study […]

Reporting from EULAR 2024: Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA

Reporting from EULAR 2024: Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA Despite the numerous treatments available, psoriatic arthritis (PsA) remains multifaceted and heterogeneous. Patient presentations and needs can vary significantly, necessitating tailored treatments. The current challenge is to find a drug that balances efficacy and safety to address these diverse patient […]

Broadcasting from EULAR 2024: Canakinumab Prophylaxis Resolves Active Gout Flares Within 48 Hours

Broadcasting from EULAR 2024: Canakinumab Prophylaxis Resolves Active Gout Flares Within 48 Hours Canakinumab prophylaxis resolves active gout flares within 48 hours and prevents new gout flares among patients initiating pegloticase + methotrexate, according to a study presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) in Vienna, Austria. The US Food and Drug Administration […]